読み込み中
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
前日終値
$13.20
−$0.05 · -0.38%
市場前
$13.15
−$0.05 · -0.38%
10月8日 9:03 ET
日中の時刻はETです。市場データは遅延する場合があります。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日中レンジ
現在 $13.20
52週レンジ
現在 $13.20
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
29
割高
センチメント
36
弱気
リスク
46
やや高いリスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日中レンジ
現在 $13.20
52週レンジ
現在 $13.20
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$18.67
上昇余地（41.44%）この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI3453万0.33%100.75億 USD0.35%$150.23-0.44%
Vanguard Morningstar Total Stock Market ETFVTI3018.21万0.00%2.3兆 USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM2783.49万0.04%785.63億 USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF1332.72万0.01%954億 USD0.05%$233.49-1.56%
iShares Biotechnology ETFIBB876.68万0.08%104.01億 USD0.44%$203.34+0.12%
Vanguard Russell 2000 ETFVTWO695.99万0.04%180億 USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA553.61万0.03%216.99億 USD0.03%$32.61-1.47%
F/M Emerald Life Sciences Innovation ETFLFSC538.7万4.64%1.16億 USD0.79%$41.8366-0.65%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAF/M Emerald Life Sciences Innovation ETFLFSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
